Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $2.1 million.

  • Keros Therapeutics' Other Non-Current Assets changed negligibly% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.1 million for FY2024, which is 0.19% up from last year.
  • Keros Therapeutics' Other Non-Current Assets amounted to $2.1 million in FY2024, which was up 0.19% from $2.1 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Other Non-Current Assets ranged from a high of $2.1 million in FY2024 and a low of $115,000 during FY2020.
  • For the 3-year period, Keros Therapeutics' Other Non-Current Assets averaged around $1.8 million, with its median value being $2.1 million (2023).
  • Data for Keros Therapeutics' Other Non-Current Assets shows a peak YoY spiked of 1,053.91% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Keros Therapeutics' Other Non-Current Assets stood at $115,000 in 2020, then soared by 1,053.91% to $1.3 million in 2021, then remained steady at $1.3 million in 2022, then spiked by 54.63% to $2.1 million in 2023, then rose by 0.19% to $2.1 million in 2024.